fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Ciprofloxacin and dexamethasone

All products: Limited Use (codes 509)

Sandoz Ciprofloxacin/Dexamethasone · DIN 02506882 · 0.3% w/v & 0.1% w/v · Otic suspension-7.5mL Pk (With Preservative)

Limited Use, Reason for Use code 509 requiredMarketed · checked November 18, 2026
StatusLimited Use, Reason for Use code 509 required
Write on scriptReason for Use code 509 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 509
Reason for Use code 509 The treatment of otitis externa in patients: - With known perforated tympanic membrane or ventilation tubes; OR - Requiring chronic therapy (i.e., more than 14 days); OR - Who have been receiving more than 7 days of topical aminoglycoside therapy without improvement, where there is concern of a resistant pathogen; OR - With documented pre-existing hearing impairment. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Ciprofloxacin/Dexamethasone · DIN 02506882 Manufacturer: Sandoz Canada Inc.; listing date 2021-03-29 Health Canada: Marketed since 2021-01-26 · brand SANDOZ CIPROFLOXACIN / DEXAMETHASONE · ATC S02CA06 DEXAMETHASONE AND ANTIINFECTIVES · form Suspension · route Otic · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 0.3 %/W/V, DEXAMETHASONE 0.1 %/W/V · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Ciprofloxacin/Dexamethasone: Formulary list price $14.42 per unit (the source does not state the unit; exact figure $14.4203). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02506882)

Source record
DIN 02506882: Sandoz Ciprofloxacin/Dexamethasone Raw flags: sec12=Y, sec3=Y Item: 520404046; group id 575; item number 1529; lccId 00306; manufacturer id SDZ Source form: Otic Susp-7.5mL Pk (With Preservative); strength: 0.3% w/v & 0.1% w/v Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $14.4203; ministry $14.4203 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02506882 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99623
Interchangeable products
Ciprodex · DIN 02252716 · $14.4203 Taro-Ciprofloxacin/Dexamethasone · DIN 02481901 · $14.4203
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (52:04:04 Antibiotics) and how they are covered

Matched class: 52:04:04 Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: FRAMYCETIN SULFATE, FRAMYCETIN SULFATE & GRAMICIDIN & DEXAMETHASONE, GENTAMICIN & BETAMETHASONE SODIUM PHOSPHATE, GENTAMICIN SULFATE, POLYMYXIN B SULFATE & BACITRACIN (ZINC), POLYMYXIN B SULFATE & GRAMICIDIN, TOBRAMYCIN, TOBRAMYCIN & DEXAMETHASONE 52:04:04 Antibiotics

FRAMYCETIN SULFATE

· 2 products · General benefit · strengths: 0.5% · Oph Oint-5g Pk, Oph Sol

FRAMYCETIN SULFATE & GRAMICIDIN & DEXAMETHASONE

· 1 products · General benefit · strengths: 5mg & 50mcg & 0.5mg/mL · Oph/Ot Sol

GENTAMICIN & BETAMETHASONE SODIUM PHOSPHATE

· 1 products · General benefit · strengths: 3mg & 1mg/mL · Oph/Ot Drops

GENTAMICIN SULFATE

· 1 products · General benefit · strengths: 0.3% · Oph Oint-3.5g Pk

POLYMYXIN B SULFATE & BACITRACIN (ZINC)

· 1 products · General benefit · strengths: 10000U & 500U/g · Oph Oint 3.5g Pk

POLYMYXIN B SULFATE & GRAMICIDIN

· 1 products · General benefit · strengths: 10000U & 0.025mg/mL · Oph/Ot Sol

TOBRAMYCIN

· 3 products · General benefit · strengths: 0.3% · Oph Oint, Oph Sol

TOBRAMYCIN & DEXAMETHASONE

· 2 products · General benefit · strengths: 0.3% & 0.1% · Oph Oint, Oph Susp

GATIFLOXACIN

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.3% w/v · Oph Sol

MOXIFLOXACIN HYDROCHLORIDE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.5% · Oph Sol-3mL Pk (Preservative-Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 52:04:04
Full class listing Related classes: 52:04:12 Other Anti-Infectives, 52:08:92 Anti-Inflammatory Agents, Miscellaneous Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: infections
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CLARITHROMYCIN · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), General benefit (15), Off-Formulary Interchangeable, not an ODB benefit (9) (For additional information on the use of BIAXIN BID® in triple therapy for the treatment of H. pylori infection and active duodenal ulcer recurrence, refer to the Hp-PAC® Product Monograph.) BIAXIN® (clarithromycin for oral suspension USP) Product Monograph Master Template Template Date: September 2020 BIAXIN BID®, BIAXIN® - clarithromycin Page 4 of 107 BIAXIN® is indicated for the treatment of infections due to susceptible organisms, in the following conditions: • Upper Respiratory Tract • Pharyngitis caused by S. pyogenes (Group A ß-hemolytic streptococci). PM: https://pdf.hres.ca/dpd_pm/00078094.PDF; date DEC 17, 2024; DIN 01984853; fetched 2026-09-10 Product monograph TETRACYCLINE · Listed, not a benefit (1), General benefit (1) Indications TETRACYCLINE (tetracycline hydrochloride capsules) is indicated for infections caused by the following microorganisms: • Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, tick fevers), M. pneumoniae (PPLO, Eaton agent), agents of psittacosis and ornithosis, agents of L. venereum and G. inguinale, and the spirochetal agent of relapsing fever (B. recurrentis). PM: https://pdf.hres.ca/dpd_pm/00084169.PDF; date 2026-03-17; DIN 00580929; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE CIPRODEX® (ciprofloxacin/dexamethasone otic suspension) is indicated for the treatment of infections caused by most strains of the designated microorganisms in the specific conditions listed below: Acute Otitis Media with Otorrhea through tympanostomy tubes in pediatric patients ≥ 6 months of age due to: Aerobic, Gram-Positive: Streptococcus pneumoniae Staphylococcus aureus Aerobic, Gram-Negative: Haemophilus influenza Moraxella catarrhalis Pseudomonas aeruginosa Acute Otitis Externa in adults and pediatric patients ≥ 1 year of age due to: Aerobic, Gram-Positive: Staphylococcus aureus Aerobic, Gram-Negative: Pseudomonas aeruginosa To reduce the development of drug-resistant bacteria and maintain the effectiveness of CIPRODEX and other antibacterial drugs, CIPRODEX should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. CIPRODEX® Product Monograph Page 3 of 20 Geriatrics (> 65 years of age): Elderly patients may be at a higher risk of developing tendon inflammation and rupture (see WARNINGS AND PRECAUTIONS, General). Pediatrics (… https://pdf.hres.ca/dpd_pm/00041611.PDF PM date: September 27, 2017 Source product: CIPRODEX; DIN 02252716; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18